NCCN Guidelines® Insights - Non-Small Cell Lung Cancer, Version 4.2016
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC; Versions 1–4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Non–Small Cell Lung Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non–Small Cell Lung Cancer
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Senior Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
David S. Ettinger, MD, Panel Chair, has disclosed that he is a scientific advisor for ARIAD Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Genentech, Inc.; Helsinn Pharmaceutical; and EMD Serono. He receives consulting fees/honoraria from Bristol-Myers Squibb Company, and receives grant/research support from Golden Biotechnology Corporation.
Douglas E. Wood, MD, Panel Vice Chair, has disclosed that he receives grant/research support from is and is a scientific advisor for
Hossein Borghaei, DO, MS, Panel Member, has disclosed that he is a scientific advisor for Bristol-Myers Squibb Company, Eli Lilly and Company, Boehringer Ingelheim GmbH, Pfizer Inc., Genentech, Inc., and Clovis Oncology; is a consultant for Bristol-Myers Squibb Company and Eli Lilly and Company; and receives research support from Millennium Pharmaceuticals, Inc.
David Ross Camidge, MD, PhD, Panel Member, has disclosed that he receives consulting fees from G1 Therapeutics, Inc.; ORION Clinical Services; ARIAD Pharmaceuticals, Inc.; Array BioPharma Inc.; Eli Lilly and Company; Novartis AG; Celgene Corporation; AbbVie Inc.; and Clovis Oncology.
Leora Horn, MD, MSc, Panel Member, has disclosed that she receives consulting fees/honoraria from Genentech, Inc. and Merck & Co., Inc.; receives research support from AstraZeneca Pharmaceuticals LP; is a scientific advisor for Xcovery, Bayer HealthCare, Bristol-Myers Squibb Company, and Boehringer Ingelheim GmbH; and is on a product/speakers’ bureau for Biodesix, Inc.
Karen Reckamp, MD, MS, Panel Member, has disclosed that she receives consulting fees/honoraria from Amgen Inc,. Astellas US LLC, Boehringer Ingelheim GmbH, Nektar Therapeutics, and ARIAD Pharmaceuticals, Inc.; she receives grant/research support from Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Xcovery, Pfizer Inc., Eisai Inc., Adaptimmune LLC, Novartis Pharmaceuticals Corporation, ARIAD Pharmaceuticals, Inc., and Clovis Oncology.
Gregory J. Riely, MD, PhD, Panel Member, has disclosed that he receives consulting fees/honoraria from Genentech, Inc.
Kristina Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Miranda Hughes, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-16-003-H01-P
All clinicians completing this activity will be issued a certificate of participation.
Release date: March 10, 2016
Expiration date: March 10, 2017
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation